GlassScriptPhysician profile
Blair W Krell
NPI 1912904731
$14,404.16
in general payments reported to CMS, 2019-2025
59 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $2,218 · 2021: $2,491 · 2022: $2,292 · 2023: $1,434 · 2024: $2,536 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837 · Consulting Fee: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,837.30 |
| Consulting Fee | $966.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,111.10 | 2021-2025 | Rytary, Crexont, Ongentys |
| Teva Pharmaceuticals USA, INC. | $1,036.53 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $989.53 | 2021-2025 | |
| Biogen, INC. | $877.72 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Neurocrine Biosciences, INC. | $834.29 | 2020-2025 | Ingrezza, Ongentys |
| Eisai INC. | $825.44 | 2019-2025 | |
| Sk Life Science, INC. | $753.05 | 2020-2025 | |
| Emd Serono, INC. | $715.41 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $678.01 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $602.95 | 2019-2024 | Nuplazid |
| Ucb, INC. | $516.26 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $498.61 | 2019-2025 | Ultomiris |
| Pfizer INC. | $475.08 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $429.01 | 2019-2021 | |
| Grifols USA, LLC | $403.80 | 2019-2025 | Gamunex-C |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Krell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.